文献速递消化系统肿瘤

高肿瘤突变负荷(TMB)识别出具有延长生存和强抗肿瘤免疫的微卫星稳定胰腺癌亚群

High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity.
PubMed 文献 · Eur J Cancer · 2022-05-02

研究评估了161例已切除的微卫星稳定(MSS)胰腺导管腺癌(PDAC)的肿瘤突变负荷(TMB),其中41例为长期生存者(LTS),另评估5例微卫星高度不稳定(MSI-high)病例。TMB-high(≥10 mut/Mb)肿瘤包含10例LTS(10/41;24%)和2例常规PDAC(2/120;1.7%),并表现出最高的T细胞密度及显著增加的CD3+CD4+辅助T细胞和CD208+树突状细胞计数。TMB-high病例常属于生存期延长的特定PDAC亚群,并显示出由辅助T细胞/树突状细胞介导的细胞毒性T细胞启动所驱动的强抗肿瘤免疫应答。

要点

  • TMB-high(≥10 mut/Mb)PDAC中LTS占24%(10/41),常规PDAC仅占1.7%(2/120)。
  • TMB-high肿瘤CD3+CD4+辅助T细胞和CD208+树突状细胞计数显著高于其他病例。
  • 所有MSI-high PDAC均为TMB-high,且TMB-high中ARID1A和ERBB4改变更频繁。

核心结论

  • TMB-high病例常属于生存期延长的特定PDAC亚群,如LTS和MSI-high PDAC。
  • TMB-high肿瘤表现出由辅助T细胞/树突状细胞介导的细胞毒性T细胞启动所驱动的强抗肿瘤免疫应答。
  • TMB-high肿瘤常携带进一步的可靶向改变。

研究设计与样本

  • 评估了161例已切除的微卫星稳定(MSS)PDAC的TMB,包括41例长期生存者(LTS)。
  • 另评估了5例微卫星高度不稳定(MSI-high)病例。
  • 病例按TMB分为TMB-high(≥10 mut/Mb)、TMB-intermediate(>5且<10 mut/Mb)和TMB-low(≤5 mut/Mb)三类。
  • 肿瘤行mRNA原位杂交检测免疫通路基因,并通过多重免疫荧光及自动图像分析进行免疫谱分析。

主要发现

  • 检出12例TMB-high、28例TMB-intermediate和121例TMB-low病例。
  • TMB-high肿瘤包含10例LTS(10/41;24%)和2例常规PDAC(2/120;1.7%)。
  • TMB-high肿瘤表现出最高的T细胞密度,CD3+CD4+辅助T细胞和CD208+树突状细胞计数较所有其他病例显著增加。
  • TMB-high PDAC中CD3+CD8+细胞毒性T细胞与肿瘤细胞距离显著更近,辅助T细胞与树突状细胞距离显著更近。
  • 多数TMB-high和许多TMB-intermediate肿瘤中,涉及T细胞活化、免疫细胞黏附/迁移、抗原呈递和细胞因子信号的免疫通路上调。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Tumor mutational burden (TMB: somatic mutations per megabase, mut/Mb) predicts the efficacy of immunotherapy. Here, we link TMB levels with the activation of immune pathways and intratumoral immune responses in pancreatic adenocarcinoma (PDAC) to explore immunoarchitectural patterns associated with high TMB. METHODS: We assessed TMB in 161 resected, microsatellite stable (MSS) PDACs, including 41 long-term survivors (LTS). Five microsatellite instable (MSI-high) cases were also assessed. Cases were classified into TMB-high (≥10 mut/Mb), TMB-intermediate (>5 < 10 mut/Mb), and TMB-low (≤5 mut/Mb) categories. Tumors additionally underwent mRNA in situ hybridization for immune pathway genes and were immunoprofiled by multiplex immunofluorescence followed by automated image analysis. RESULTS: We detected 12 TMB-high, 28 TMB-intermediate, and 121 TMB-low cases. TMB-high tumors comprised ten LTSs (10/41; 24%) and two conventional PDACs (2/120; 1.7%). They exhibited the highest T cell density with significantly increased CD3+CD4+T helper and CD208+dendritic cell (DC) counts, compared to all other cases. CD3+CD8+cytotoxic T cells were significantly closer to tumor cells and T helper cells closer to DCs in TMB-high PDACs. Immune pathways involved in T cell activation, immune cell adhesion/migration, antigen presentation, and cytokine signaling were upregulated in most TMB-high and many TMB-intermediate tumors. ARID1A and ERBB4 alterations were more frequent in TMB-high PDACs. All MSI-high PDACs were TMB-high. CONCLUSIONS: TMB-high cases frequently belong to specific PDAC subsets with prolonged survival such as LTSs and MSI-high PDACs. They display strong anti-tumor immune responses fueled by a T helper cell/DC-mediated priming of the cytotoxic T cells. Moreover, they frequently harbor further actionable alterations.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Karamitopoulou E, Andreou A, Wenning AS, et al. High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity. Eur J Cancer. 2022. PMID: 35512587. doi:10.1016/j.ejca.2022.03.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。